Anti-neurodegenerative natural compound isolated from alpiniae oxyphyllae fructose and their total synthesis

Patent metadata

Field	Value
Publication number	US-9475749-B2
Application number	US-201414210467-A
Country	US
Kind code	B2
Filing date	Mar 14, 2014
Priority date	Mar 14, 2013
Publication date	Oct 25, 2016
Grant date	Oct 25, 2016

Abstract

This invention is directed to novel compounds isolated or derived from Alpiniae oxyphyllae fructus, chemically synthesized novel compounds, methods of preparing the novel compounds and uses thereof as neuroprotectants or drugs for treating neurodegenerative diseases such as Parkinson's disease.

First claim

What is claimed is:

1. A compound with Formula I:

wherein R 1 and R 3 are independently H or unsubstituted or substituted (C1-C3) alkyl;
R 2 is H or substituted (C1-C3) alkyl; and
R 4 is H or substituted (C1-C3) alkyl,
wherein, the compound is an isolated and purified ((R)-4-(2-hydroxy-5-methylphenyl)-5-methylhexanoic acid).

2. A compound with Formula I:

wherein R 1 and R 3 are independently H or unsubstituted or substituted (C1-C3) alkyl;
R 2 is H or substituted (C1-C3) alkyl; and
R 4 is H or substituted (C1-C3) alkyl,

wherein the compound is ((S)-4-(2-hydroxy-5-methylphenyl)-5-methylhexanoic acid) or (4-(2-hydroxy-5-methylphenyl)-5-methylhexanoic acid).

3. A compound with Formula I:

wherein
R 1 is H or substituted (C1-C3) alkyl;
R 3 is unsubstituted or substituted (C1-C3) alkyl; and
R 2 and R 4 are independently H or unsubstituted or substituted (C1-C3) alkyl,
wherein R 1 is substituted (C1-C3) alkyl; R 3 is unsubstituted or substituted (C1-C3) alkyl; and R 2 and R 4 are H.

4. A compound with Formula I:

wherein R 1 and R 3 are independently H or unsubstituted or substituted (C1-C3) alkyl;
R 2 is substituted (C1-C3) alkyl; and
R 4 is H or unsubstituted or substituted (C1-C3) alkyl,
wherein R 1 and R 3 are independently unsubstituted or substituted (C1-C3) alkyl; and R 4 is H.

Assignees

• Univ Macau

Inventors

• Lee Ming Yuen
• Zhang Zaijun
• Li Guohui

Classifications

• A61P25/16

  Anti-Parkinson drugs · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• C07C51/47

  by solid-liquid treatment; by chemisorption · CPC title

• C07C51/347

  by reactions not involving formation of carboxyl groups · CPC title

• C07C59/52 Primary

  a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring · CPC title